Vor Biopharma Inc. 8-K

What Happened

• Vor Biopharma Inc. announced the results of its June 2026 Annual Meeting of Stockholders in an 8‑K filed June 12, 2026. About 34,012,004 shares were present or represented (≈62.77% of voting stock).
• Stockholders elected two Class II directors — Andrew Levin, M.D., Ph.D., and Fouad Namouni, M.D. — to serve until the 2029 annual meeting.
• Stockholders approved an Amendment and Restatement of the company’s Amended and Restated 2021 Equity Incentive Plan; the amended plan is filed as Exhibit 10.1 to the 8‑K.
• Stockholders ratified Ernst & Young LLP as Vor Biopharma’s independent registered public accounting firm for the year ending December 31, 2026.

Key Details

• Votes for director elections:
  • Andrew Levin: For 25,797,081; Withheld 120,813; Broker non‑votes 7,094,110.
  • Fouad Namouni: For 22,825,938; Withheld 4,091,956; Broker non‑votes 7,094,110.
• Amended 2021 Equity Incentive Plan vote: For 20,146,430; Against 6,767,428; Abstain 4,036; Broker non‑votes 7,094,110.
• Auditor ratification vote: For 33,877,004; Against 133,499; Abstain 1,501.
• The 8‑K was signed by CEO Jean‑Paul Kress on June 12, 2026.

Why It Matters

• Governance: Election of two directors fills Class II board seats through 2029, which affects board composition and oversight continuity.
• Compensation & dilution: Approval of the amended 2021 Equity Incentive Plan permits the company to grant equity awards under the updated plan terms (the plan text is included as Exhibit 10.1); this can affect future employee incentives and potential share dilution.
• Audit continuity: Ratifying Ernst & Young LLP confirms the firm that will audit Vor Biopharma’s 2026 financial statements, which is relevant to financial reporting continuity and investor confidence.

Keywords: annual meeting, proxy vote, director election, equity incentive plan, auditor ratification, Vor Biopharma.